Combining cutting-edge proprietary technologies and enhanced manufacturing, TG4070 is positioned as a novel vaccine relevant to multiple tumor types
TG4070, the second candidate from the myvac® platform:
• Full internalized AI-driven capabilities with SNIPER, a novel neoantigen prediction tool
• Scalable cell-line manufacturing designed to support faster vaccine supply and broader platform deployment
• New randomized Phase 1 trial in combination with immune checkpoint inhibitor in adjuvant NSCLC – Patient screening to start in coming weeks
TG4050, the first candidate from the myvac® platform, continues to progress in Phase 2, with topline data expected in Q1 2028. Plan to move to cell-line manufacturing for potential next trials in HNSCC
Conference call scheduled on June, 29 at 3 p.m. CET / 9:00 a.m. ET (see details below).
Webcast registration: https://lifescievents.com/event/ri20slf0/
.../...
0 commentaire
Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement
Signaler le commentaire
Fermer